| __timestamp | Agios Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 13774000 |
| Thursday, January 1, 2015 | 35992000 | 22479000 |
| Friday, January 1, 2016 | 50714000 | 27388000 |
| Sunday, January 1, 2017 | 71124000 | 35610000 |
| Monday, January 1, 2018 | 114145000 | 49007000 |
| Tuesday, January 1, 2019 | 132034000 | 61139000 |
| Wednesday, January 1, 2020 | 149070000 | 68836000 |
| Friday, January 1, 2021 | 121445000 | 97592000 |
| Saturday, January 1, 2022 | 121673000 | 106903000 |
| Sunday, January 1, 2023 | 119903000 | 120998000 |
| Monday, January 1, 2024 | 156784000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Agios Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Agios Pharmaceuticals saw a staggering 526% increase in SG&A expenses, peaking in 2020. Meanwhile, Vericel Corporation experienced an impressive 779% rise, with a notable surge in 2023, surpassing Agios for the first time. This shift highlights Vericel's aggressive expansion strategy. The data reveals a competitive landscape where both companies are investing heavily in administrative and sales functions to drive growth. As the biotech sector continues to evolve, monitoring these financial metrics provides valuable insights into corporate strategies and market positioning.
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.